Squamous cell carcinoma antigen: A potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin

Cancer

Volumn 119, Issue 13, 2013, Pages 2391-2398

  Williams, Matt ^a   Swampillai, Angela ^b   Osborne, Melanie ^c   Mawdsley, Suzannah ^b   Hughes, Rob ^b   Harrison, Mark ^b   Harvey, Richard ^d   Glynne Jones, Rob ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

anal carcinoma; disease free survival; recurrence; squamous cell carcinoma antigen; tumor markers

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; MITOMYCIN; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CANCER OF THE ANAL CANAL AND MARGIN; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

ADULT; AGED; ANAL CANAL; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SERPINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879101637     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28055     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Bilimoria KY, Bentrem DJ, Rock CE, et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009; 52: 624-631.
3. Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984; 54: 114-125.
4. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal cooperative groups. J Clin Oncol. 1997; 15: 2040-2049.
5. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996; 348: 1049-1054.
6. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14: 2527-2539.
7. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 199: 1914-1921.
8. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]. J Clin Oncol. 2009; 27: 18s. Abstract LBA4009.
9. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial Working Party. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer. 2013; 119: 748-755.
10. Kato H, Torigoe T,. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977; 40: 1621-1628.
11. Kato H, Tamai K, Morioka H, et al. Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer. 1984; 54: 1544-1546.
12. Ferrandina G, Macchia G, Legge F, et al. Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Oncology. 2008; 74: 42-49.
13. Hong JH, Tsai CS, Chang JT, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41: 823-830.
14. Ogino I, Nakayama H, Okamoto N, et al. The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy. Int J Gynecol Cancer. 2006; 16: 1094-1100.
15. Chen SW, Liang JA, Hung YC, et al. Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix. Tumour Biol. 2008; 29: 255-261.
16. Noordhuis MG, Eijsink JJ, Roossink F, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys. 2011; 79: 325-334.
17. Fontana X, Lagrange Jl, Francois E, et al. Assessment of "squamous cell carcinoma antigen" (SCC) as a marker of epidermoid carcinoma of the anal canal. Dis Colon Rectum. 1991; 34: 126-131.
18. Petrelli NJ, Palmer M, Herrera L, Bhargava A,. The utility of squamous cell carcinoma antigen for the follow-up of patients with squamous cell carcinoma of the anal canal. Cancer. 1992; 70: 35-39.
19. Indinnimeo M, Reale MG, Cicchini C, et al. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors. Int Surg. 1997; 82: 275-279.
20. Goldman S, Svensson C, Bronnergard M, et al. Prognostic significance of serum concentration of squamous cell carcinoma antigen in anal epidermoid carcinoma. Int J Colorectal Dis. 1993; 8: 98-102.
21. McShane LM, Altman DG, Sauerbrei W, et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. J Clin Oncol. 2005; 23: 9067-9072.
22. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors. 5th ed. New York: John Wiley & Sons, Inc.; 1997.
23. Kobayashi E,. A Chemiluminescent microparticle squamous cell carcinoma associated antigen assay for the ARCHITECT Instrument System. Paper presented at: 32nd Meeting of the International Society of Oncology and Biomarkers; June 19-23, 2004; Helsinki, Finland.
24. The ARCHITECT Instrument System [product insert]. North Chicago, IL: Abbott; 2004. Available at: www.abbottdiagnostics.co.uk/webapp/index.cfm?event= getPDF&controlNumber=F502012R2 11/10/09, 2009. [Accessed March 21, 2013].
25. James R, Meadows H, Wan S,. ACT II: the second UK phase III anal cancer trial. Clin Oncol. 2005; 17: 364-366.
26. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available at: http://www.R-project.org. [Accessed March 21, 2013].
27. Crombach G, Scharl A, Vierbuchen M, et al. Detection of squamous cell carcinoma antigen in normal squamous epithelia and in squamous cell carcinoma of the uterine cervix. Cancer. 1989; 63: 1337-1342.
28. Lee DW, Kim YT, Kim JH, et al. Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol. 2010; 21: 18-23.
29. Crombach G, Wurz H, Kreienberg R,. Evaluation of SCC antigen as a tumour marker for cervical cancer: a co-operative study of GTMG. Tumour Marker Oncol. 1988; 3: 59-63.
30. Reesink-Peters N, van der Velden J, Ten Hoor KA, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early stage cervical cancer. J Clin Oncol. 2005; 23: 1455-1462.
31. Molina R, Filella X, Lejarcegui JA, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003; 24: 156-164.
32. Micke O, Prott FJ, Schafer U, et al. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000; 20: 5113-5115.
33. Pras E, Willemse PH, Canrinus AA, et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys. 2002; 52: 23-32.
34. Chan YM, Ng TY, Ngan HYS, et al. Monitoring of serum squamous cell antigen levels in invasive cervical cancer: is it cost effective? Gynecol Oncol. 2002; 84: 7-11.
35. Forni F, Ferrandina G, Deodato F, et al. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost effectiveness. Int J Radiat Oncol Biol Phys. 2007; 69: 1145-1149.
36. Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N,. Relevance of SCCAg, CEA, CA 199 and CA 125 for diagnosis and follow up in oral cancer. J Craniomaxillofac Surg. 1998; 26: 243-248.
37. Lachowicz MA, Hassmann-Poznanska E, Kozlowski MD, et al. Squamous cell carcinoma antigen in patients with cancer of the larynx. Clin Otolarngol Allied Sci. 1999; 24: 270-273.
38. Pintor MP, Northover JM, Nicholls RJ,. Squamous cell carcinoma of the anus at 1 hospital from 1948 to 1984. Br J Surg. 1989; 76: 806-810.
39. De Nardi P, Carvello M, Canevari C, Passoni P, Staudacher C,. Sentinel node biopsy in squamous-cell carcinoma of the anal canal. Ann Surg Oncol. 2011; 18: 365-370.